Recombinant human albumin (rHu Albumin) is a sterile, stable, and non-pyrogenic solution containing minimum 99% purified albumin. Albumin is the most abundant protein in human blood plasma and serves to regulate the colloidal osmotic pressure of blood and acts as a transport and reservoir protein. rHu Albumin finds numerous therapeutic applications such as in burns, shocks, hypovolemia, hypoalbuminemia, hemodialysis, and assisted reproductive technology. With rising surgical procedures and increasing adoption of rHu Albumin as therapeutic agent, the global market is witnessing significant growth.

The global rHu Albumin Market is estimated to be valued at US$ 14.16 Mn in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
The rising usage of rHu Albumin in therapeutic applications owing to its various functional properties is a key driver for market growth over the forecast period. rHu Albumin is used as volume expander to treat hypoalbuminemia in patients suffering from liver diseases and nephrotic syndrome. It helps in maintaining effective circulation volume as well as tissue perfusion in patients. Furthermore, it also finds usage as stabilizing agent in formulations of biotherapeutics and vaccines. The expanding biopharmaceutical industry and increasing research & development of protein-based therapeutics are expected to drive the demand for rHu Albumin over the next few years.

SWOT Analysis
Strength: rHu Albumin is one of the leading albumin products used globally. It has wide therapeutic applications such as hypovolemia, hypoalbuminemia and other critical care indications. Its extensive use over the past few decades has established its efficacy and safety profile in the pharmaceutical industry. Being a human recombinant protein, it has higher purity levels compared to plasma-derived albumin products.
Weakness: The manufacturing process of rHu Albumin is complex involving bioengineering techniques and requires high capital investments which increases its production costs. The regulatory norms for biopharmaceutical development are stringent limiting ease of market entry for new players.
Opportunity: Increasing prevalence of chronic diseases and critical care procedures globally is driving the demand for albumin products. The elderly population who often require albumin supplementation is on the rise in developing nations providing new opportunities. Alternate applications of rHu Albumin in fields like biomedical research holds promise.
Threats: Development of alternative therapy strategies and albumin-sparing volume expansion fluids can replace albumin usage to some extent. Prices of competing plasma-derived albumin products fluctuate based on plasma availability affecting sales. Regulatory delays and biosimilar approvals pose pricing and market share threats.

Key Takeaways
Global rHu Albumin Market Size is expected to witness high growth over the forecast period driven by increased clinical adoption. The global rHu Albumin Market is estimated to be valued at US$ 14.16 Mn in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030.

North America presently dominates the market owing to advanced healthcare facilities and availability of reimbursements for rHu Albumin therapy. The Asia Pacific region is expected to witness fastest gains due to growing investments to strengthen healthcare systems, greater acceptance of biopharmaceuticals and rising medical tourism in the region. China in particular holds high potential attributed to large population base, increasing spending on healthcare.

Key players
Key players operating in the rHu Albumin market include Cerner Corporation, Elekta, Accuray, RaySearch Laboratories, Flatiron Health, Koninklijke Philips N.V., McKesson Corporation, Epic Systems Corporation, CureMD Healthcare, Varian Medical Systems, Inc. Cerner Corporation has a major presence in the hospital EHR segment while Philips has wide offerings in the medical imaging solutions domain. 

Get More Insights on this Topic- https://www.timessquarereporter.com/health/rhu-albumin-market-is-estimated-to-witness-high-growth-owing-to-the-growing-healthcare-sector